This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Patients aged ≥18 years old
Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;
Prior or current use of BTK inhibitor for ≥3 months
None
Investigators participating in this observational study should include all patients with CLL who initiated treatment with BTK inhibitor over the period from Dec. 1st, 2017 to the present, regardless of the treatment status at the time of inclusion. Thus, at the time of enrolment and retrospective data collection, patients may still be on treatment or have stopped treatment for any reason.
Cohort
Retrospective
BTK inhibitor
Drugpatients with treatment naive or R/R CLL who treatment with BTK inhibitor
Overall Survival
OS is defined as the time from the starting date of BTK inhibitor to the date of death due to any cause.
Time to Next Therapy (TTNT)
The TTNT will be calculated as the difference between BTK inhibitor initiation date and initiation date of the first next therapy for CLL
Adverse Events
Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
